Morc4 Inhibitors
Morc4 inhibitors encompass a variety of compounds that indirectly suppress the activity of Morc4 by targeting specific signaling pathways or cellular processes. For instance, inhibitors that target protein kinase C can diminish Morc4 function by impacting the chromatin remodeling and gene expression regulation that Morc4 is associated with. Similarly, compounds that inhibit histone deacetylases or DNA methyltransferases can affect Morc4 by altering the epigenetic landscape, consequently changing the chromatin context and gene expression patterns that Morc4 regulates. Proteasome inhibitors can also modulate the stability of regulatory proteins involved in controlling Morc4 activity, thereby indirectly influencing Morc4's functional state. Additionally,inhibitors of the PI3K pathway can indirectly suppress Morc4 activity by modulating downstream signaling and gene expression that are critical for Morc4's role in the cell.
Inhibitors that impede the MAPK signaling cascade, including those targeting MEK or p38 MAPK, can influence Morc4 activity by altering gene expression and chromatin dynamics that Morc4 is involved in. The inhibition of pathways upstream of ERK can also affect Morc4 function by changing the cellular milieu in which Morc4 operates, such as MEK1/2 inhibitors that indirectly reduce Morc4 activity through these mechanisms. Additionally, compounds that inhibit GSK-3 can indirectly suppress Morc4 by impacting transcriptional programs crucial for Morc4 expression. Furthermore, mTOR inhibitors play a role in indirectly inhibiting Morc4 by affecting cell growth and proliferation, which are processes that can influence the cellular context of Morc4's activity. Lastly, Akt inhibitors can modulate Morc4 function by altering signaling pathways related to cell survival and metabolism, which can have downstream effects on Morc4's expression and activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
This compound is a potent and selective inhibitor of protein kinase C (PKC), which is involved in various signaling pathways including those regulating chromatin remodeling and gene expression. By inhibiting PKC, bisindolylmaleimide I can lead to the decreased functional activity of Morc4, as Morc4 is implicated in chromatin remodeling processes. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase (HDAC) inhibitor that alters chromatin structure to regulate gene expression. Morc4 is associated with chromatin remodeling; inhibition of HDAC can therefore indirectly inhibit Morc4 activity by affecting the chromatin context in which it operates. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound is a DNA methyltransferase inhibitor that leads to hypomethylation of DNA. As DNA methylation can affect chromatin structure and gene expression, 5-Azacytidine can indirectly inhibit Morc4 by altering the epigenetic landscape and modulating its interaction with chromatin. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins, potentially leading to altered protein levels that affect various cellular processes. By inhibiting proteasome activity, MG-132 can indirectly affect Morc4 function by stabilizing regulatory proteins that may control Morc4 activity or expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a phosphatidylinositol 3-kinase (PI3K) inhibitor. Given that PI3K signaling is crucial for numerous cellular processes, including gene expression, LY 294002 may indirectly inhibit Morc4 by modulating signaling pathways that regulate its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This compound is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK signaling pathway. As MAPK signaling can influence gene expression and chromatin dynamics, PD 98059 could indirectly inhibit Morc4 by impacting these regulatory mechanisms. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor, which can affect cellular responses to stress and inflammation. By inhibiting p38 MAPK, the compound could indirectly inhibit Morc4 by modulating stress-response pathways that Morc4 may be involved in. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of the ERK pathway. By inhibiting this pathway, U0126 could affect gene expression patterns and indirectly inhibit Morc4 by altering the cellular context in which it functions. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
This is a potent inhibitor of PI3K. Wortmannin's inhibition of PI3K signaling could indirectly inhibit Morc4 by affecting downstream signaling that may regulate Morc4's activity or stability. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
A selective inhibitor of glycogen synthase kinase 3 (GSK-3), can influence Wnt signaling and thereby gene expression. By inhibiting GSK-3, this compound could indirectly inhibit Morc4 by affecting the transcriptional programs that regulate its expression. | ||||||